ANA Therapeutics
VerifiedFounded in response to the COVID-19 pandemic, we’re investigating niclosamide as a treatment for COVID-19.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$20—30m (Dealroom.co estimates Aug 2020.)
San Mateo California (HQ)
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | $0.0 | round |
| N/A | $0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | $0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
Recent News about ANA Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.